ArticleInvestigational new drugs2012

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.

Sang Joon Shin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.